By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Researchers detail new data in Immunization. According to news reporting from Houston, Texas, by NewsRx journalists, research stated, "Significant progress has been made in the field of cancer immunotherapy, where the goal is to activate or modulate the body's immune response against cancer. However, current immunotherapy approaches exhibit limitations of safety and efficacy due to systemic delivery."
The news correspondents obtained a quote from the research from Rice University, "In this context, the use of nanotechnology for the delivery of cancer vaccines and immune adjuvants presents a number of advantages such as targeted delivery to immune cells, enhanced therapeutic effect, and reduced adverse outcomes. Recently, gold nanoparticles (AuNP) have been explored as immunotherapy carriers, creating new AuNP applications that merit a critical overview. This review highlights recent advances in the development of AuNP mediated immunotherapies that harness AuNP biodistribution, optical properties and their ability to deliver macromolecules such as peptides and oligonucleotides. It has been demonstrated that the use of AuNP carriers can improve the delivery and safety of immunotherapy agents, and that AuNP immunotherapies are well suited for synergistic combination therapy with existing cancer therapies like photothermal ablation. Cancer immunotherapy approaches are rapidly evolving and are some of the most promising avenues to approach malignancies."
According to the news reporters, the research concluded: "This review summarizes the role of gold nanoparticles in immunotherapy agent delivery, and in the development of synergistic therapies such as photothermal ablation."
For more information on this research see: Gold nanoparticle mediated cancer immunotherapy. Nanomedicine, 2014;10(3):503-14. (Elsevier - www.elsevier.com; Nanomedicine - www.elsevier.com/wps/product/cws_home/703416)
Our news journalists report that additional information may be obtained by contacting J.P. Almeida, Dept. of Bioengineering, Rice University, Houston, TX, United States. Additional authors for this research include E.R. Figueroa and R.A Drezek (see also Immunization).
Keywords for this news article include: Texas, Houston, Oncology, Immunization, United States, Nanotechnology, Cancer Vaccines, Gold Nanoparticles, Combination Therapy, Emerging Technologies, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC